The development of in vitro–in vivo extrapolation (IVIVE), a 'bottom-up'approach, to predict
pharmacokinetic parameters and drug–drug interactions (DDIs) has accelerated mainly due …

In adapting to the challenge to make more informed selection of compounds for
development, the pharmaceutical industry is increasingly embracing the application of …

Classic pharmacokinetics (PK) rarely takes into account the full knowledge of physiology
and biology of the human body. However, physiologically based PK (PBPK) is built mainly …

An increasing number of failures in clinical stages of drug development have been related to
the effects of candidate drugs in a sub-group of patients rather than theaverage'person …

Drug–drug interactions (DDIs) are associated with severe adverse effects that may lead to
the patient requiring alternative therapeutics and could ultimately lead to drug withdrawal …

Abstract Background and Objective The In Vivo Mechanistic Static Model (IMSM) is a
powerful method used to predict the magnitude of drug–drug interactions (DDIs) mediated …

Pharmacokinetic drug–drug interactions (DDIs) occur when a drug alters the absorption,
transport, distribution, metabolism or excretion of a co-administered agent. The occurrence …

Poly-therapy is common due to co-occurrence of several ailments in patients, leading to the
elevated possibility of drug–drug interactions (DDI). Pharmacokinetic DDI often accounts for …

Prediction of in vivo drug-drug interactions (DDIs) from in vitro and in vivo data, also named
in vitro in vivo extrapolation (IVIVE), is of interest to scientists involved in the discovery and …

Physiologically‐based pharmacokinetic (PBPK) modeling has been extensively used to
quantitatively translate in vitro data and evaluate temporal effects from drug–drug …